Option Care Health, Inc. provides home and alternate-site infusion services for patients with acute and chronic conditions across the United States. The company operates in infusion services and reports developments tied to clinical service delivery, national provider relationships, and the economics of its care model.
Recurring news for OPCH includes quarterly and full-year financial results, guidance updates, operating cash flow, share repurchase activity, credit facility changes, and presentations at health care investor conferences. Company updates also address capital allocation and management commentary related to revenue growth and profitability in home and alternate-site infusion care.
Option Care Health (Nasdaq: OPCH) will participate in the 46th Annual TD Cowen Healthcare Conference in Boston on Tuesday, March 3, 2026, including a fireside chat at 1:10 PM ET. The company will webcast the presentation at its investor site.
Option Care Health is described as the nation’s largest independent provider of home and alternate site infusion services, with over 8,000 team members and more than 5,000 clinicians serving all 50 states.
Option Care Health (NASDAQ: OPCH) will release its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026 before the market opens. Management will host a conference call to review the results at 8:30 a.m. ET the same day.
Participants can pre-register for the call via the provided registration link and listen via a live audio webcast at investors.optioncarehealth.com. A replay will be available on the same webcast link for approximately 90 days after the call.
Option Care Health (Nasdaq: OPCH) reported preliminary unaudited results for Q4 and full year 2025 and provided preliminary guidance for full year 2026. Q4 2025 net revenue is expected to be $1.46–1.47B, GAAP diluted EPS $0.37–0.39, adjusted diluted EPS $0.46–0.49, and adjusted EBITDA $123.7–127.7M. Full year 2025 net revenue is expected at $5.645–5.655B, GAAP diluted EPS $1.27–1.29, adjusted diluted EPS $1.72–1.76, adjusted EBITDA $469–473M, and operating cash flow below $320M. 2026 guidance calls for net revenue $5.8–6.0B, adjusted diluted EPS $1.82–1.92, and adjusted EBITDA $480–505M. The board expanded the share repurchase authorization to $1.0B (added $500M); ~$307M was repurchased in 2025.
Option Care Health (Nasdaq: OPCH) will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 with a presentation at 10:30am PT.
The company said the webcast and presentation materials will be available at https://investors.optioncarehealth.com. Option Care Health describes itself as the nation’s largest independent provider of home and alternate site infusion services, with over 8,000 team members including more than 5,000 clinicians serving all 50 states.
Option Care Health (Nasdaq: OPCH) will participate in four investor conferences in November–December 2025, presenting corporate updates and fielding investor questions.
Schedule: UBS Global Healthcare in Palm Beach on Nov 11, 2025 at 3:30pm ET; Jefferies London Healthcare in London on Nov 19, 2025 at 3:30pm GMT; Bank of America Leveraged Finance in Boca Raton on Dec 2, 2025 at 10:50am ET; and Bank of America Home Care (virtual) on Dec 8, 2025 at 10:50am ET.
Webcasts and presentation materials, if applicable, will be available at https://investors.optioncarehealth.com. The company states it employs over 8,000 team members including more than 5,000 clinicians and provides home and alternate site infusion services across all 50 states.
Option Care Health (Nasdaq: OPCH) reported third-quarter 2025 results for the period ended September 30, 2025: net revenue $1.435B (+12.2% YoY), gross profit $272.9M (+6.3% YoY), net income $51.8M (-3.8% YoY) and GAAP diluted EPS $0.32. Adjusted metrics: Adjusted EBITDA $119.5M (+3.4% YoY) and Adjusted diluted EPS $0.45 (+9.8% YoY). The company repurchased $62.5M of stock in the quarter, expanded a term loan by $49.6M with a lower rate, and reported YTD operating cash flow of $222.6M.
Updated 2025 guidance: revenue $5.60–5.65B, Adjusted EPS $1.68–1.72, Adjusted EBITDA $468–473M, and cash flow from operations ≥ $320M.
Option Care Health (NASDAQ: OPCH), the largest independent provider of home and alternate site infusion services in the US, has scheduled its Q3 2025 earnings release for Thursday, October 30, 2025, before market opens.
The company will host a conference call at 8:30 a.m. ET on the same day to discuss the results. Investors can pre-register for the call or access it via webcast at investors.optioncarehealth.com. A replay will be available for approximately 90 days after the call.
Option Care Health (NASDAQ:OPCH), the largest independent provider of home and alternate site infusion services in the US, announced its participation in two upcoming investor conferences. The company will attend the Deutsche Bank Healthcare Summit in New York City (September 10-11, 2025) and the Jefferies Healthcare Services Conference in Nashville (September 30, 2025), where they will participate in a fireside chat at 2:15pm ET.
Option Care Health operates nationwide with over 8,000 team members, including more than 5,000 clinicians, providing infusion services for patients with acute and chronic conditions across all 50 states.
Option Care Health (Nasdaq: OPCH), the largest independent provider of home and alternate site infusion services in the US, announced a significant leadership transition. Meenal Sethna will join as Executive Vice President and CFO effective October 1, 2025, succeeding Mike Shapiro, who will step down after 10 years with the company.
Sethna brings over 30 years of experience and most recently served as EVP and CFO at Littelfuse, Inc. Shapiro will remain as Strategic Advisor through Q1 2026 to ensure a smooth transition. The change comes as Option Care Health maintains strong momentum in its mission to deliver extraordinary care and create long-term shareholder value.
Quince Therapeutics (Nasdaq: QNCX) announced significant progress in Q2 2025, highlighted by the completion of enrollment in its pivotal Phase 3 NEAT clinical trial for A-T treatment. The trial enrolled 105 participants, with topline results expected in Q1 2026. The company secured financing that brought its cash position to $34.7 million, providing runway through Phase 3 results into Q2 2026.
Key financial results include R&D expenses of $6.6 million, G&A expenses of $3.3 million, and a net loss of $16.1 million ($0.34 per share). Quince entered a strategic partnership with Option Care Health for U.S. commercial launch support and closed a premium-priced private placement led by Nantahala Capital, generating $11.5 million in upfront proceeds with potential additional proceeds of up to $10.4 million from warrants.